Condition: Advanced Solid Tumor · Sponsor: Gilead Sciences
This is a first-in-human (FIH) study to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of denikitug (also known as GS-1811) as monotherapy and in combination with zimberelimab in participants with advanced solid tumors. This study will be conducted in 6 parts (Parts A, B, and E: monotherapy, Parts C and D: combination therapy, and Part F for both monotherapy and combination therapy) in participants with advanced solid tumors who have received, been intolerant to, or been ineligible for all treatments known to confer clinical benefit or in participants with select solid tumors.
This description comes directly from the study's public registry record.
Gilead Clinical Study Information Center · 1-833-445-3230 (GILEAD-0) · GileadClinicalTrials@gilead.com
Always discuss trial participation with your own doctor first.
| University of California San Diego | La Jolla, California, United States | Recruiting |
| Stanford Cancer Center | Palo Alto, California, United States | Recruiting |
| Smilow Cancer Center | New Haven, Connecticut, United States | Completed |
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | Recruiting |
| Tennessee Oncology, PLLC | Nashville, Tennessee, United States | Recruiting |
| University of Texas Southwestern Medical Center | Dallas, Texas, United States | Recruiting |
| Sarah Cannon Research Institute at Mary Crowley | Dallas, Texas, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| NEXT Oncology | San Antonio, Texas, United States | Recruiting |
| University of Wisconsin Clinical Sciences Center | Madison, Wisconsin, United States | Recruiting |
| Chris O'Brien Lifehouse | Camperdown, New South Wales, Australia | Recruiting |
| Monash Medical Centre | Clayton, Victoria, Australia | Recruiting |
+ 14 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05007782